CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Trastuzumab for Breast and Gastric Cancer Biosimilar – Details

Project Number PC0160-000
Brand Name TBD
Generic Name Trastuzumab
Tumour Type Breast & Gastrointestinal
Indication Breast and Gastric Cancer Biosimilar
Funding Request Breast and Gastric Cancer Biosimilar
Review Status Cancelled
Pre Noc Submission Yes
NOC Date
Manufacturer Pfizer Canada Inc.
Sponsor Pfizer Canada Inc.
Submission Date (Target Date) May 15, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ May 30, 2019
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.